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Abstract 
Rho GTPases play a pivotal role in tumor progression by regulating tumor cell migration and invasion. 
However, the role of Rho GTPases in gastric cancer (GC) remains unexplored. This study aimed to 
investigate the clinical implications of RhoJ, which is an uncharted member of Rho family. RhoJ 
expression in human GC cell lines and surgical specimens from GC patients were analyzed. Moreover, 
in vitro gain-of-function analysis was performed to evaluate the malignant phenotypes of 
RhoJ-overexpressing GC cells. The extent of RhoJ expression varied among GC cell lines and GC 
patients. YCC-9 cell line displayed the strongest expression, while YCC-10, -11, and -16 showed scant 
expressions. Of the 70 GC patients, 34 (48.6%) had RhoJ expression in their GC tissue, and patients 
with high RhoJ expression had more diffuse type GC (73.5% vs. 41.7%), were at more advanced stages 
(stage III, IV: 85.3% vs. 58.4%), and had more frequent metastasis (47.1% vs. 11.1%), denoting that RhoJ 
has a potential role in GC progression and metastasis. High RhoJ expression significantly correlated with 
poor overall survival and recurrence-free survival after surgical resection of gastric cancer. Finally, In 
vitro gain-of-function experiments showed 41.3% enhanced motility and 60.4% enhanced invasiveness in 
RhoJ-overexpressing GC cells compared to control, with negligible difference in cell proliferation. 
Collectively, high RhoJ expression is an independent negative prognostic factor for the survival outcome 
of GC and correlated with the increased cell motility and invasiveness. 
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Introduction 
Gastric cancer (GC) is one of the most prevalent 
malignancies worldwide [1]. Despite recent 
therapeutic advances, the overall prognosis of 
recurrent or metastatic GC remains dismal, thereby 
necessitating the unearthing of novel therapeutic 
targets in GC [2-4]. 
The invasive and migratory capability of 
malignant tumor cells into neighboring 
microenvironment is the most critical step that 
governs the entire process of tumor progression [5, 6]. 
Among the prime mediators which are responsible for 
tumor cell migration and invasion, one particular 
family of proteins that seems to play a decisive role is 
Rho GTPase [7-9]. They are molecular switches which 
regulate various intracellular processes such as 
cytoskeletal rearrangement, thereby playing 
important roles in every aspects of tumor progression 
including malignant transformation, proliferation, 
invasion, and metastasis of tumor cells [8-10]. Among 








are most extensively studied where their 
overexpression was found to be closely related to GC 
progression, while other members are largely 
uncharted [10]. 
RhoJ is a recently identified member of Rho 
family [11, 12]. Although RhoJ shares structural 
similarities and common effector molecules with 
other Rho GTPases, it has other distinct characteristics 
[12-14]. Recently published study demonstrates that 
RhoJ is enriched in endothelial cells and plays a 
positive angiogenic role during tumor progression 
and wound healing [15]. However, little is known 
regarding the role of RhoJ in non-endothelial cells 
such as tumor cells. Intriguingly, few recent studies 
have been published regarding the expression of RhoJ 
in melanoma cells and addressed its role in the 
regulation of melanoma cell migration and invasion 
[16, 17]. Considering these findings, we set out to 
investigate the possible role of RhoJ during GC 
progression. 
In the present study, we aimed to demonstrate 
the correlation between RhoJ expression and 
clinicopathologic parameters as well as to uncover the 
putative role of RhoJ in regulating GC cell behavior. 
Materials and Methods 
Cell culture and transfection 
Human gastric cancer cell lines, YCC-1, YCC-2, 
YCC-3, YCC-7, YCC-9, YCC-10,YCC-11, and YCC-16 
were established by Yonsei Cancer Center (Seoul, 
Korea) from GC patients through the isolation of 
blood (YCC-16) or ascites (others cell lines). Cells were 
incubated in RPMI-1640 (Welgene) with 10% fetal 
bovine serum (FBS) in 5% CO2 at 37°C. Human 
umbilical vein endothelial cells (HUVEC, Lonza) were 
cultured in endothelial growth medium (EGM-2, 
Lonza). Full-length human RhoJ expression vector 
and an empty vector were acquired from Addgene 
(http://addgene.org). YCC-16 cells were transfected 
with either the RhoJ expression vector or empty 
vector by using Lipofectamine LTX (Life 
Technologies) following the manufacturer’s 
instruction. 
Western blotting 
Cell lysates were separated with SDS-PAGE and 
transferred to PVDF membranes (Millipore). The 
membranes were blocked with 5% skim milk, 
followed by the incubation with the following 
primary antibodies: RhoJ (mouse monoclonal, 
Abnova) and GAPDH (rabbit polyclonal, Santacruz). 
The bound antibodies were visualized with 
HRP-conjugated secondary antibodies. Signals were 
developed with HRP substrate and detected with 
LAS-1000 (Fuji film). 
Proliferation assay 
The cells were placed in a 96-well plate at a 
concentration of 5×103 cells per well. After incubation 
for 1 to 3 days, the amount of viable cells was 
determined using the water-soluble tetrazolium assay 
(WST) kit (DaeilLab). After incubating the cells with 
WST solution for 20 min at 37°C, optical absorbance 
was measured with a microplate reader (Bio-Rad). 
Migration assay 
4×104 cells were seeded in serum-free medium 
onto the upper chamber of 24-well culture inserts 
with 8 μm pores (Millipore) and medium containing 
5% FBS was placed in the lower chamber. After 24 hr, 
the cells on the upper surface of membrane were 
removed with a cotton swab. The cells that had 
migrated to the lower surface of membrane were fixed 
and visualized with 1% crystal violet (Sigma). 
Invasion assay 
Cell invasion was compared using BioCoat 
MatrigelTM invasion chambers (BD). 4×104 cells were 
plated in the upper chamber in serum-free medium 
and the lower chamber was filled with medium 
containing 10% FBS. After 36 hours, the cells on the 
upper surface were removed with a cotton swab. The 
cells that had migrated through the MatrigelTM 
invasion chamber were fixed and visualized with 1% 
crystal violet.  
Patients and surgical specimens 
70 patients who were diagnosed with primary 
gastric adenocarcinoma and received radical 
gastrectomy were enrolled at Yonsei Cancer Center, 
Severance Hospital (Yonsei University Health System, 
Seoul, Korea). The clinicopathologic variables 
including age, sex, histologic type, Lauren’s 
classification, stage, type of surgery, and survival 
outcome were reviewed retrospectively based on the 
electronic medical records. Pathological diagnosis and 
staging of GC was made according to the American 
Joint Committee on Cancer 2010 staging system. The 




Immunohistochemical (IHC) staining was 
performed on the surgical specimens of GC patients. 
Slides were antigen-retrieved by autoclaving and 
blocked. Samples were incubated with RhoJ antibody 
(mouse monoclonal clone 1E4, Abnova) overnight, 
followed by incubation with biotinyated secondary 
antibody. Slides were reacted with Vectastatin ABC 
reagent (Vector laboratories) and DAB (DAKO) was 




used as a chromogen. The following scoring system 
was used to grade RhoJ immunoreactivity: score 0 = 
no staining or non-specific staining of tumor cells; 
score 1 = weak and incomplete staining of >10% of 
tumor cells; score 2 = moderate and complete staining 
of >33% of tumor cells; score 3 = strong and complete 
staining of >67% of tumor cells. Those with >10% 
positive stained tumor cells (scores 1 to 3) were 
regarded to be RhoJ-positive. RhoJ immunoreactivity 
in endothelial cells was excluded from analysis. For 
immunofluorescent (IF) staining, cells cultured on 
coverslips were blocked and incubated overnight 
with the phospho-histone H3 antibody (Cell 
Signaling). Then, slides were incubated with 
cy3-conjugated secondary antibodies (Jackson 
ImmunoResearch). Nuclei were stained with DAPI 
(Invitrogen) and F-actin was stained with Acti-stain 
Phalloidin (Cytoskeleton). Then the slides were 
mounted and imaged with a LSM510 confocal 
microscope (Carl Zeiss). 
Statistical analysis 
Survival curves were estimated with the 
Kaplan-Meier method, and the statistical differences 
were determined using the log-rank test. Overall 
survival (OS) was calculated from the date of 
gastrectomy to the date of death, while 
recurrence-free survival (RFS) was defined as the 
interval between the date of gastrectomy and the date 
of either recurrence or death. Multivariate analyses 
were performed with the Cox proportional hazard 
model. Chi-square tests and independent sample 
t-test were used for the analysis of variables. All 
statistical analyses were carried out with SPSS version 
12.0 (SPSS, Inc.). 
Results 
Human GC cell lines express RhoJ differently 
At first, we compared the expression of RhoJ 
proteins in various human GC cell lines and HUVECs 
using immunoblotting. The expression levels of RhoJ 
differed among different GC cell lines, with the 
highest in YCC-9 cell line, in which the expression 
level of RhoJ was higher than that of human 
endothelial cell, HUVEC, while being barely 
detectable in YCC-10, -11, and -16 cell lines (Figure 
1A). These findings suggest that human GC cells also 
express RhoJ as well as endothelial cells. 
High RhoJ expression is associated with diffuse 
type GC at later stages and poor survival 
outcome as well as more frequent distant 
metastasis 
To evaluate the expression of RhoJ in GC tissues 
in addition to the cell lines, we performed IHC 
staining for 70 cases of surgically resected GC 
specimens. IHC staining results displayed RhoJ 
expression in GC tissues with varied intensities 
(Figure 1B). When the intensity of RhoJ expression 
was graded as negative (≤10% of cells stained) or 
positive (>10% of cells stained), of the 70 GC tumor 
specimens, 34 (48.6%) displayed the expression of 
RhoJ, while 36 (51.4%) did not show any expression of 
RhoJ. We were able to observe the strong expression 
of RhoJ in cytoplasm of tumor cells, while it was 
occasionally expressed in tumor vasculatures 
(Figure 1C). 
 
Figure 1. RhoJ expression in GC cell lines and surgical specimens of GC patients. (A) Various GC cell lines and HUVECs were cultured for 24 hr and 
harvested.  Immunoblotting showing differential levels of RhoJ expression in various GC cell lines and HUVEC. EC, endothelial cell. (B) Immunohistochemical staining 
showing RhoJ expression in GC tissue. Scale bar: 200 μm. (C) Endothelial expression of RhoJ in GC tissue. Arrows indicate the endothelial expression of RhoJ. Scale 
bar: 200 μm. 




The baseline characteristics of the patient cohort 
are summarized in Table 1. The median age at the 
time of GC diagnosis was 62 years (range 33-83) and 
the male-to-female ratio was 1.9. The most common 
histologic type was tubular adenocarcinoma (70%) 
and 57.1% of tumors were classified as diffuse type by 
Lauren’s classification. Almost all patients (94.3%) 
received adjuvant chemotherapy, while only 2 out of 
70 patients (2.9%) underwent adjuvant radiotherapy. 
The median follow-up duration was 47.5 months and 
47.1% of patients were alive at the time of analysis. 
To characterize the features of GC patients with 
RhoJ expression, various clinicopathologic parameters 
were compared according to the RhoJ expressing 
status (Table 2). Patients with RhoJ-positive tumors 
had more diffuse type GC (73.5% vs. 41.7%, p=0.007) 
at later stages (stage III, IV: 85.3% vs. 58.4%, p=0.023) 
and distant metastasis (47.1% vs. 11.1%, p=0.001), 
denoting that RhoJ has a positive role in tumor 
progression and metastasis. In addition, RhoJ-positive 
tumors tended to be more poorly differentiated 
adenocarcinoma and signet ring cell carcinoma 
compared to RhoJ-negative tumors (82.4% vs. 52.8%, 
p=0.043). However, there were no significant 
differences in age, sex, T stage, and N stage between 
RhoJ-positive and RhoJ-negative GC patients. 
Moreover, the proportion of patients receiving 
adjuvant chemotherapy or radiotherapy was not 
different between RhoJ-negative and RhoJ-positive 
groups. 
Table 1. Baseline characteristics of the cohort. 
 N (%) (n=70) 
Age (median, range) 62 (33-83) 
Sex  
Male 46 (65.7) 
Female 24 (34.3) 
Histology  
WD 3 (4.3) 
MD 17 (24.3) 
PD 29 (41.4) 
SRC 18 (25.7) 
Others 3 (4.3) 
Lauren classification  
Intestinal 30 (42.9) 
Diffuse 40 (57.1) 
Stage  
IIA 10 (14.3) 
IIB 10 (14.3) 
IIIA 4 (5.7) 
IIIB 8 (11.4) 
IIIC 18 (25.7) 
IV 20 (28.6) 
Type of surgery  
Total gastrectomy 36 (51.4) 
Subtotal gastrectomy 34 (48.6) 
Adjuvant therapy  
Adjuvant chemotherapy 66 (94.3) 
Adjuvant radiotherapy 2 (2.9%)  
WD, well differentiated; MD, moderately differentiated; 
PD, poorly differentiated; SRC, signet ring cell. 
High RhoJ expression is associated with poor 
survival outcome in GC patients 
On Kaplan-Meier survival analysis, 
RhoJ-positive group displayed markedly poorer OS 
and RFS compared with RhoJ-negative group 
(p=0.001 and 0.002, respectively) (Figure 2A and 2B).  
Next, we further examined the prognostic value 
of high RhoJ expression with adjustments for other 
prognostic factors with a Cox’s multivariate analysis 
(Table 3). Even after the adjustment, high RhoJ 
expression still conferred a significant impact on OS 
and RFS of GC patients (p=0.038 and p=0.047, 
respectively), indicating that it is an independent 
prognostic factor for OS and RFS. Collectively, these 
findings evidence that high RhoJ expression is a 
negative prognostic factor for the survival outcome of 
GC patients. 
Table 2. Correlation between RhoJ expression and clinical parameters. 
 RhoJ-negative (n=36) RhoJ-positive (n=34) p-value 
Age 61 (33-76) 59 (33-83) 0.865 
Sex   0.863 
Male 24 (66.7) 22 (64.7)  
Female 12 (33.3) 12 (35.3)  
Histology   0.043 
WD and MD 15 (41.7) 5 (14.7)  
PD and SRC 19 (52.8) 28 (82.4)  
Others 2 (5.5) 1 (2.9)  
Lauren classification   0.007 
Intestinal 21 (58.3) 9 (26.5)  
Diffuse 15 (41.7) 25 (73.5)  
Stage   0.023 
IIA 7 (19.4) 3 (8.8)  
IIB 8 (22.2) 2 (5.9)  
IIIA 2 (5.6) 2 (5.9)  
IIIB 5 (13.9) 3 (8.8)  
IIIC 10 (27.8) 8 (23.5)  
IV 4 (11.1) 16 (47.1)  
T stage   0.411 
T2 4 (11.1) 4 (11.8)  
T3 10 (27.8) 4 (11.8)  
T4a 19 (52.8) 22 (64.7)  
T4b 3 (8.3) 4 (11.8)  
N stage   0.467 
N0 8 (22.2) 3 (8.8)  
N1 9 (25.0) 7 (20.6)  
N2 4 (11.1) 6 (17.6)  
N3a 13 (36.1) 14 (41.2)  
N3b 2 (5.6) 4 (11.8)  
M stage   0.001 
M0 32 (88.9) 18 (52.9)  
M1 4 (11.1) 16 (47.1)  
Table 3. Prognostic factor for OS and RFS in multivariate Cox regression 
model. 
 OS  RFS  
HR (95% CI) p-value HR (95% CI) p-value 
Age (≥65 vs. <65) 0.70 (0.35-1.41) 0.314 0.39 (0.18-0.85) 0.018 
RhoJ (Positive vs. 
Negative) 
2.68 (1.30-5.53) 0.038 2.09 (1.01-4.32) 0.047 
Histology (PD, SRC vs. 
WD, MD) 
1.44 (0.72-2.88) 0.302 1.56 (0.78-3.12) 0.213 
Stage (III, IV vs. II) 2.74 (1.13-6.65) 0.025 3.03 (1.13-8.11) 0.027 




RhoJ overexpression enhanced GC cell 
migration and invasion in vitro 
To elucidate the role of RhoJ overexpression on 
the biologic behavior of GC cells, we established 
RhoJ-overexpressing (RhoJ-OV) cells by transfecting 
YCC-16 GC cell lines with RhoJ-expressing plasmid 
(Figure 3A). The overexpression of RhoJ in RhoJ-OV 
cells did not affect the proliferation of GC cells 
compared to empty-vector transfected control 
(RhoJ-WT) cells (Figure 3B). In addition, there was no 
difference in the proportion of PH3+ proliferating cells 
between RhoJ-OV and RhoJ-WT cells (Figures 3C and 
3D), indicating that RhoJ has negligible role in the 
regulation of GC cell proliferation. On the other hand, 
RhoJ-OV cells displayed 41.3% increase in cell 
motility across the membrane of cell culture inserts 
(p=0.015) (Figures 3E and 3F). Moreover, RhoJ-OV 
cells had 60.4% enhanced invasion ability across the 
MatrigelTM extracellular matrix compared to RhoJ-WT 
cells (p=0.024) (Figures 3G and 3H). Taking these 
results together, we were able to confirm that RhoJ in 
GC cell plays an important role in the regulation of 
GC cell motility and invasiveness. 
Discussion 
Rho GTPases regulate diverse cellular processes 
such as cytoskeletal rearrangement, cell motility, 
cell-cycle progression, and transcription [9,10]. 
Though there are increasing number of preclinical 
evidences reporting the importance of Rho GTPases 
during tumor progression and metastasis [8-10], the 
clinical significance of Rho GTPases in human cancer 
is largely unknown, especially in GC. Only few 
studies reported increased expression of RhoA, RhoC, 
and Rac1 in GC and their prognostic role in 
GC [10,18,19].  
Inspired by these recent results in the role of 
RhoJ in melanoma [16,17], we explored whether RhoJ 
is also expressed in GC tissue. Intriguingly, in human 
GC, RhoJ was predominantly expressed in tumor cells 
with occasional expression in some part of tumor 
vasculatures. This finding implies that the cells 
responsible for RhoJ expression may vary according 
to the types of cancer. In GC, RhoJ expression in 
tumor cells seems to be more prevailing compared to 
endothelial RhoJ expression. Moreover, we examined 
whether RhoJ expression has a potential clinical value 
in GC patients. As a result, we were able to confirm 
the varied expression of RhoJ in GC cell lines and GC 
tissues, and could demonstrate that high RhoJ 
expression is a negative prognostic factor for the OS 
and RFS of GC patients after curative surgery. Even 
after adjustment for other prognostic factors, high 
RhoJ expression had significantly negative influence 
on survival outcome of GC patients. To our 
knowledge, this is the first study to demonstrate the 
independent prognostic value of RhoJ in human 
cancer. 
We were also able to discover the possible 
mechanism in which RhoJ leads to the progression 
and metastasis of GC. Our in vitro experiments 
displayed the increased motility and invasiveness of 
GC cells where RhoJ was forcefully overexpressed by 
the transfection of RhoJ-expression vector compared 
to control GC cells, while there was no difference in 
terms of GC cell proliferation. This in vitro evidence 
suggests that the increased progression and 
metastasis observed in RhoJ-high GC patients might 
be attributed to the enhanced migratory and invasive 




Figure 2. RhoJ expression is a negative prognostic factor for GC patients. (A) Kaplan-Meier analysis of overall survival (OS) in RhoJ-positive and 
RhoJ-negative GC patients. (B) Kaplan-Meier analysis of recurrence-free survival (RFS) in RhoJ-positive and RhoJ-negative GC patients. 





Figure 3. RhoJ-overexpressing GC cells have enhanced migratory and invasion ability. YCC-16 cells were transfected with either empty or 
RhoJ-expressing vectors using Lipofectamine. Unless otherwise denoted: Values are mean ± standard deviations. n=5. *p<0.05 versus RhoJ-WT. (A) RhoJ expression 
level was compared by immunoblotting 24 hr after transfection. RhoJ-overexpressing (RhoJ-OV) cells displayed markedly increased RhoJ expression compared to 
control (RhoJ-WT) cells. (B) The effect of RhoJ expression on GC cell proliferation. Cell viability was evaluated using WST assay on the indicated time points after 
transfection. (C and D) Images and quantification of PH3+ proliferating cells. (E and F) Images and quantification of GC cell migration across cell culture insert after 
24 hr of incubation. (G and H) Images and quantification of GC cell invasion across Matrigel extracellular matrix after 36 hr of incubation. 
 
Despite the novel findings of our study, one 
critical question that remained to be answered in the 
future is whether RhoJ is a feasible therapeutic target 
for the treatment of GC. For the moment, there is no 
direct evidence indicating the therapeutic value of 
RhoJ blockade in human cancer. However, previous 
studies employing animal tumor models could 
provide some hints to this question. The previous 
work that focused on endothelial RhoJ showed that 
the genetic deletion of host-derived RhoJ could 
suppress tumor progression and metastasis through 
the inhibition of tumor angiogenesis [15]. Besides, Ho 
et al. reported that the knockdown of RhoJ in 
melanoma cell with shRNA could delay melanoma 
growth and lymphatic metastasis [17]. Therefore, the 
strategy of targeting RhoJ has the potential of 
dual-targeting of tumor cells and tumor vessels 
simultaneously. This hypothesis has to be validated 
with animal models of GC when RhoJ inhibitors are 
developed and become available. 
In conclusion, the current study presents 
evidence that RhoJ is positively associated with the 
regulation of tumor cell motility and invasiveness in 
GC. Moreover, we were able to demonstrate that high 
RhoJ expression in GC is an independent negative 
prognostic factor after gastrectomy. Further studies 
are required to validate the therapeutic role of RhoJ in 
GC by using RhoJ-specific inhibitor.  
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